Elan drops higher-dose trials of drug

Irish-based drug company Elan, as well as Transition Therapeutics, have dropped the two highest doses of their experimental Alzheimers drug from a clinical trial following nine deaths.

It raises doubts over whether or not the drug will now get to market.